mRNA-1010の新興薬剤に関する洞察と市場予測：2032年

mRNA-1010は、Moderna社が初めて臨床に投入する季節性インフルエンザmRNAワクチン候補です。mRNA-1010は、WHOがインフルエンザ予防のために推奨している4種類のインフルエンザ株（インフルエンザA/H1N1、A/H3N2、インフルエンザB/Yamagata-およびB/Victoria-lineages）のヘマグルチニン糖タンパク質をコードする4価ワクチン候補です。HAは主要なインフルエンザ表面糖タンパク質であり、インフルエンザに対する広範な防御を生み出す重要な標的であると考えられており、現在利用可能なインフルエンザワクチンの主要な標的です。

12月には、4価インフルエンザワクチンであるmRNA-1010の第I相試験の中間結果が良好であったことに基づき、同社は、高齢者および若年成人において、最低用量でも4つのインフルエンザ株すべてに対して力価を上昇させることに成功し、安全性に重大な懸念はなかったと発表しました。これらは、季節性インフルエンザ、SARS-CoV-2、およびRSVの循環株に適応した汎呼吸器系単回投与ブースターワクチンの開発に向けた重要なマイルストーンとなっています。

当レポートでは、主要7ヶ国におけるmRNA-1010市場について調査し、市場の概要とともに、2025年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 季節性インフルエンザに対するmRNA-1010の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 mRNA-1010市場評価

• 季節性インフルエンザに対するmRNA-1010の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における季節性インフルエンザに対するmRNA-1010の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: mRNA-1010, Clinical Trial Description, 2023
• Table 2: mRNA-1010, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: mRNA-1010 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: mRNA-1010 Market Size in the US, in USD million (2019-2032)
• Table 7: mRNA-1010 Market Size in Germany, in USD million (2019-2032)
• Table 8: mRNA-1010 Market Size in France, in USD million (2019-2032)
• Table 9: mRNA-1010 Market Size in Italy, in USD million (2019-2032)
• Table 10: mRNA-1010 Market Size in Spain, in USD million (2019-2032)
• Table 11: mRNA-1010 Market Size in the UK, in USD million (2019-2032)
• Table 12: mRNA-1010 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: mRNA-1010 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: mRNA-1010 Market Size in the United States, USD million (2019-2032)
• Figure 3: mRNA-1010 Market Size in Germany, USD million (2019-2032)
• Figure 4: mRNA-1010 Market Size in France, USD million (2019-2032)
• Figure 5: mRNA-1010 Market Size in Italy, USD million (2019-2032)
• Figure 6: mRNA-1010 Market Size in Spain, USD million (2019-2032)
• Figure 7: mRNA-1010 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: mRNA-1010 Market Size in Japan, USD million (2019-2032)

“"mRNA-1010 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about mRNA-1010 for seasonal influenza in the seven major markets. A detailed picture of the mRNA-1010 for seasonal influenza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mRNA-1010 for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mRNA-1010 market forecast analysis for seasonal influenza in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.

Drug Summary:

mRNA-1010 is Moderna's first seasonal influenza mRNA vaccine candidate to enter the clinic. The mRNA-1010 is a quadrivalent vaccine candidate that encodes for hemagglutinin glycoproteins of the four influenza strains recommended by the WHO for the prevention of influenza, including influenza A/H1N1, A/H3N2, and Influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines.

In December, based on the positive interim results of the Phase I study of the quadrivalent flu vaccine, mRNA-1010, the company announced the successfully boosted titers against all four flu strains in older and younger adults, even at the lowest dose, with no significant safety concerns. These were important milestones toward developing an annual pan-respiratory single-dose booster vaccine adapted to the circulating strains of seasonal influenza, SARS-CoV-2, and RSV.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the mRNA-1010 description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
• Elaborated details on mRNA-1010 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the mRNA-1010 research and development activities in seasonal influenza across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around mRNA-1010.
• The report contains forecasted sales of mRNA-1010 for seasonal influenza till 2032.
• Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
• The report also features the SWOT analysis with analyst views for mRNA-1010 in seasonal influenza.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

mRNA-1010 Analytical Perspective by DelveInsight

• In-depth mRNA-1010 Market Assessment

This report provides a detailed market assessment of mRNA-1010 for seasonal influenza in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• mRNA-1010 Clinical Assessment

The report provides the clinical trials information of mRNA-1010 for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence mRNA-1010 dominance.
• Other emerging products for seasonal influenza are expected to give tough market competition to mRNA-1010 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of mRNA-1010 in seasonal influenza.
• Our in-depth analysis of the forecasted sales data of mRNA-1010 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the mRNA-1010 in seasonal influenza.

Key Questions

• What is the product type, route of administration and mechanism of action of mRNA-1010?
• What is the clinical trial status of the study related to mRNA-1010 in seasonal influenza and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the mRNA-1010 development?
• What are the key designations that have been granted to mRNA-1010 for seasonal influenza?
• What is the forecasted market scenario of mRNA-1010 for seasonal influenza?
• What are the forecasted sales of mRNA-1010 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to mRNA-1010 for seasonal influenza?
• Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?

Table of Contents

1. Report Introduction

2. mRNA-1010 Overview in seasonal influenza

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. mRNA-1010 Market Assessment

• 5.1. Market Outlook of mRNA-1010 in seasonal influenza
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of mRNA-1010 in the 7MM for seasonal influenza
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of mRNA-1010 in the United States for seasonal influenza
  • 5.3.2. Market Size of mRNA-1010 in Germany for seasonal influenza
  • 5.3.3. Market Size of mRNA-1010 in France for seasonal influenza
  • 5.3.4. Market Size of mRNA-1010 in Italy for seasonal influenza
  • 5.3.5. Market Size of mRNA-1010 in Spain for seasonal influenza
  • 5.3.6. Market Size of mRNA-1010 in the United Kingdom for seasonal influenza
  • 5.3.7. Market Size of mRNA-1010 in Japan for seasonal influenza

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options